Knight Therapeutics Inc (TSE:GUD) has been assigned an average rating of “Buy” from the six research firms that are currently covering the stock. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is C$9.83.

GUD has been the subject of several research reports. TD Securities increased their price objective on Knight Therapeutics from C$10.00 to C$11.00 and gave the company a “buy” rating in a research report on Friday, November 11th. Bloom Burton reissued an “accumulate” rating on shares of Knight Therapeutics in a research report on Thursday, November 10th. Scotiabank reduced their price objective on Knight Therapeutics from C$10.00 to C$9.50 and set an “outperform” rating for the company in a research report on Friday, November 11th. Finally, CIBC increased their price objective on Knight Therapeutics from C$9.50 to C$9.80 in a research report on Friday, November 11th.

Shares of Knight Therapeutics (TSE:GUD) opened at 10.10 on Monday. Knight Therapeutics has a 12-month low of $5.89 and a 12-month high of $10.36. The company has a 50-day moving average of $9.22 and a 200 day moving average of $8.67. The firm has a market cap of $1.34 billion and a P/E ratio of 71.13.

About Knight Therapeutics

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.